HemaCare Corporation Sustainability Profile
HemaCare Corporation, a leading provider in the biotechnology sector, is headquartered in the United States and operates extensively across North America. Founded in 1978, HemaCare has established itself as a pivotal player in the field of human cellular products, specialising in the collection, processing, and distribution of blood components and cellular therapies. The company’s core offerings include a range of high-quality leukapheresis products and customised cell processing services, which are distinguished by their commitment to quality and regulatory compliance. HemaCare's innovative approach has positioned it as a trusted partner for research institutions and pharmaceutical companies, contributing significantly to advancements in regenerative medicine and immunotherapy. With a strong market presence and a reputation for excellence, HemaCare continues to drive progress in the biotechnology landscape.
DitchCarbon Score
How does HemaCare Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HemaCare Corporation's score of 57 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HemaCare Corporation, headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Charles River Laboratories International, Inc., which means that any emissions data or climate commitments may be inherited from this parent organisation. As part of its corporate family relationship, HemaCare Corporation aligns with the sustainability initiatives and targets set by Charles River Laboratories. This includes participation in various climate-related initiatives such as the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Charles River Laboratories. However, specific reduction targets or achievements for HemaCare Corporation itself have not been disclosed. In summary, while HemaCare Corporation is committed to climate action through its association with Charles River Laboratories, detailed emissions data and specific reduction targets for HemaCare are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is HemaCare Corporation's Industry?
How Carbon Intensive is HemaCare Corporation's Location?
HemaCare Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HemaCare Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
